1. Search Result
Search Result
Results for "

triglyceride

" in MedChemExpress (MCE) Product Catalog:

179

Inhibitors & Agonists

2

Screening Libraries

4

Fluorescent Dye

5

Biochemical Assay Reagents

1

Peptides

34

Natural
Products

1

Recombinant Proteins

8

Isotope-Labeled Compounds

1

Antibodies

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112132
    Palmitodiolein
    1 Publications Verification

    triglyceride POO; Glycerol dioleate palmitate; 1,2-Dioleoyl-3-palmitoylglycerol

    Others Metabolic Disease
    Palmitodiolein (Triglyceride POO) is a triacylglycerol which is present in vegetable oils.
    Palmitodiolein
  • HY-135087
    Caprylic/Capric Triglyceride
    1 Publications Verification

    Biochemical Assay Reagents Others
    Caprylic/Capric Triglyceride is the triglycerides and esters prepared from fractionated vegetable oil sources and fatty acids from coconuts and palm kernel oils. Caprylic/Capric Triglyceride possesses excellent oxidation stability. Caprylic/Capric Triglyceride is used as a food additive and used in cosmetics .
    Caprylic/Capric Triglyceride
  • HY-Y1911

    Biochemical Assay Reagents Others
    Mid-chain triglyceride of caprylic/caprolic acid can be used as a co-solvent.
    Mid-chain triglyceride of caprylic/caprolic acid
  • HY-113955

    Microsomal Triglyceride Transfer Protein (MTP) Metabolic Disease
    CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo .
    CP-346086
  • HY-127035

    Glycerol tristearate

    Endogenous Metabolite Others
    Tristearin is a triglyceride derived from three units of stearic acid .
    Tristearin
  • HY-E70277

    ATGL Metabolic Disease
    Hexadecyl-CoA is a thioether analog of acyl-CoA that can inhibit adipose triglyceride lipase (ATGL) .
    Hexadecyl-CoA
  • HY-W709553

    triglyceride

    Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Glyceryl Triformate (Triglyceride) is the major form of storage and transport of fatty acids within cells and in the plasma. Glyceryl Triformate forms lipoproteins with cholesterol ester, and participates in the blood circulation. Glyceryl Triformate can lead to hypertriglyceridemia (HTG), which increases the risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis .
    Glyceryl Triformate
  • HY-113955A

    Microsomal Triglyceride Transfer Protein (MTP) Metabolic Disease
    CP-346086 dihydrate is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo .
    CP-346086 dihydrate
  • HY-119220

    JTT-130

    Microsomal Triglyceride Transfer Protein (MTP) Metabolic Disease
    Granotapide (JTT-130) is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces absorption of cholesterol and triglycerides through inhibition of MTP. Granotapide can be used for the research of dyslipidemia .
    Granotapide
  • HY-127035R

    Endogenous Metabolite Others
    Tristearin (Standard) is the analytical standard of Tristearin. This product is intended for research and analytical applications. Tristearin is a triglyceride derived from three units of stearic acid .
    Tristearin (Standard)
  • HY-121755

    CP 18524

    Others Metabolic Disease
    Tibric acid (CP 18524) has similar effects to those of hypolipidemic agents. Tibric acid has orally active triglyceride-lowering effects. Tibric acid can be used for research of hypertriglyceridemia .
    Tibric acid
  • HY-N8214

    Others Cardiovascular Disease
    Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells .
    Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside
  • HY-131389

    Others Others
    Cholesteryl heptadecanoate is a cholesteryl ester internal standard that accurately determines the concentration of free cholesterol in cells without hydrolyzing triglycerides. Cholesteryl heptadecanoate can be used for the quantitative determination of cholesteryl esters by GC or LC mass spectrometry .
    Cholesteryl heptadecanoate
  • HY-153491

    ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx

    Apolipoprotein Cardiovascular Disease
    Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
    Olezarsen
  • HY-N9535

    Others Metabolic Disease
    tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells .
    tert-OMe-byakangelicin
  • HY-156259

    Acyltransferase Metabolic Disease
    PF-07202954 is a weakly basic DGAT2 inhibitor with an IC50 of 10 nM for human DGAT2. PF-07202954 lowers liver triglyceride content in a Western-diet-fed rat model .
    PF-07202954
  • HY-D0213

    Fluorescent Dye Others
    Sudan Black B, a fat-soluble diazo dye, is a histochemical stain. Sudan Black B can be used for staining of neutral triglycerides and lipids .
    Sudan Black B
  • HY-121417

    Others Metabolic Disease
    Laserpitin, a coumarin, increases serum HDL levels, especially apoE-HDL, and decreases the hepatic triglyceride content in stroke-prone spontaneously hypertensive rats (SHRSP) .
    Laserpitin
  • HY-163452

    Others Metabolic Disease
    Squalene synthase-IN-2 (comppund isomer A-(1S, 3R)-14i) is an orally active squalene synthase inhibitor with IC50 values of 3.4, 99 nM for squalene synthase and cholesterol synthesis, respectively. Squalene synthase-IN-2 reduces plasma cholesterol and triglyceride .
    Squalene synthase-IN-2
  • HY-135297

    Biochemical Assay Reagents Others
    Mono-and diglycerides is formed by triglycerides being broken down by pancreatic lipase in the gastrointestinal lumen. Mono-and diglycerides is a food additive used as a nonionic emulsifier and mainly present in food fats .
    Mono-and diglycerides
  • HY-119964

    Others Cardiovascular Disease
    Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic agent and potently reduces the concentration of cholesterol and triglycerides .
    Cetaben
  • HY-106011

    Others Metabolic Disease
    SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia .
    SLX-4090
  • HY-118934

    Others Neurological Disease Metabolic Disease
    Novocebrin is a central nervous system activator that effectively increases brain and femoral blood flow in dogs. In addition, Novocebrin inhibits triglyceride biosynthesis in porcine adipose tissue .
    Novocebrin
  • HY-169117

    Glucosidase Metabolic Disease
    α-Glucosidase-IN-74 (Compound 7d), an isatin-thiazole derivative, is a α-glucosidase inhibitor. α-Glucosidase-IN-74 exhibits antidiabetic activity by decreasing glycaemia and triglyceride levels in Streptozotocin (HY-13753)-induced diabetic animals .
    α-Glucosidase-IN-74
  • HY-139230

    Cannabinoid Receptor PPAR Metabolic Disease
    OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .
    OLHHA
  • HY-161939

    PCSK9 Cardiovascular Disease
    7030B-C5 is a PCSK9 inhibitor (IC50=1.61 μM). 7030B-C5 can significantly reduce plasma cholesterol and triglyceride (TG) levels in vivo and slow the progression of atherosclerosis. 7030B-C5 can be used in the study of cardiovascular diseases .
    7030B-C5
  • HY-109500

    meso-Nordihydroguaiaretic acid; meso-NDGA

    Lipoxygenase Metabolic Disease Cancer
    Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .
    Masoprocol
  • HY-133556

    AMPK Metabolic Disease
    IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders .
    IQZ23
  • HY-106278A

    PPAR Metabolic Disease
    GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
    GW 590735 sodium
  • HY-121798

    PPAR Metabolic Disease
    TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes .
    TZD18
  • HY-23199

    Acyltransferase Metabolic Disease
    H2-003 is a selective human DGAT2 inhibitor that inhibits triglyceride (TG) biosynthesis. H2-003 also effectively inhibits lipid droplet formation in 3T3-L1 cells. H2-003 can be used for research on DGAT2 and TG-related metabolic diseases .
    H2-003
  • HY-110381

    Acyltransferase Metabolic Disease
    JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis .
    JNJ-DGAT2-A
  • HY-123402
    GSK3987
    1 Publications Verification

    LXR Metabolic Disease
    GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation .
    GSK3987
  • HY-17504D

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Cardiovascular Disease Metabolic Disease
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    (3S,5R)-Rosuvastatin
  • HY-17504C

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Cardiovascular Disease Metabolic Disease
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    (3R,5R)-Rosuvastatin
  • HY-148944

    Reactive Oxygen Species Apoptosis Cancer
    Didocosahexaenoin, an omega-3 derivative, is a diglyceride of DHA and can be synthesised from DHA triglycerides. Didocosahexaenoin causes significant loss of mitochondrial membrane potential and induces ROS production. Didocosahexaenoin induces apoptosis. Didocosahexaenoin induces stronger cytotoxicity than DHA in human prostate carcinoma cells .
    Didocosahexaenoin
  • HY-W011404
    Tributyrin
    1 Publications Verification

    Glyceryl tributyrate

    Apoptosis Metabolic Disease Cancer
    Tributyrin (Glyceryl tributyrate), a neutral short-chain fatty acid triglyceride, is a stable and rapidly absorbed proagent of Butyric Acid. Tributyrin diffuses through biological membranes and is metabolized by intracellular lipases, releasing effective butyrate directly into the cell in vivo. Tributyrin has potent antiproliferative, proapoptotic and differentiation-inducing effects .
    Tributyrin
  • HY-161985

    PPAR Metabolic Disease
    PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .
    PPARγ-IN-3
  • HY-168533

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .
    ZG-2305
  • HY-16278
    Pradigastat
    2 Publications Verification

    LCQ-908

    Acyltransferase BCRP OAT Infection Metabolic Disease
    Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
    Pradigastat
  • HY-16278A

    LCQ 908 sodium

    Acyltransferase BCRP OAT Infection Metabolic Disease
    Pradigastat sodium (LCQ 908 sodium) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
    Pradigastat sodium
  • HY-W015309

    iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .
    Decanoic acid
  • HY-100313A
    YM-53601
    2 Publications Verification

    Farnesyl Transferase HCV Infection Metabolic Disease
    YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601
  • HY-17504B
    Rosuvastatin Sodium
    10+ Cited Publications

    ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Cardiovascular Disease Metabolic Disease
    Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Sodium
  • HY-W015309R

    iGluR Tyrosinase c-Met/HGFR Glutaminase Neurological Disease Metabolic Disease Cancer
    Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .
    Decanoic acid (Standard)
  • HY-100313

    Farnesyl Transferase HCV Metabolic Disease
    YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601 free base
  • HY-N7055

    Endogenous Metabolite Metabolic Disease
    Trierucin is a trierucic acid triglyceride from the seed oil .
    Trierucin
  • HY-17504
    Rosuvastatin Calcium
    10+ Cited Publications

    Rosuvastatin hemicalcium; ZD 4522 Calcium

    HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium
  • HY-N6660

    Tricaprin; Glyceryl tridecanoate

    Endogenous Metabolite Androgen Receptor Cardiovascular Disease Metabolic Disease
    Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .
    Trisdecanoin
  • HY-17504BS2

    ZD 4522-13C,d3 sodium; X-Plended-13C,d3 sodium; Crestor-13C,d3 sodium

    Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease
    Rosuvastatin- 13C,d3 sodium is 13C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin-13C,d3 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: